Use in Jey of FTO/SB/17 (08-03) (Form updated to reflect FY 2004 fees effective 10/1/03)

PER TRALIGISTAL			Complete if Known						
FEE TRANSMITTAL	.	Applic	noites	Numb	er 09/246,129-Conf	09/246,129-Conf. #5810			
for FY 2004	Filing Date				February 8, 1999	February 8, 1999			
			Vameo	Inver	nor Guo-Liang Yu	Guo-Liang Yu			
Etiocuva 10/01/2003, Patent feed are dubject to annual revision		Examiner Name			D. Romeo	D. Romeo			
Applicant claims small entity status See 37 CFR 1 27		Art Ur	hit		1647	1647			
TOTAL AMOUNT OF PAYMENT (\$) 0.00				CKOT NO	o. PF141P4	PF141P4			
METHOD OF PAYMENT (check all that apply)	T			FFF	CALCULATION (continued)				
Cons. Filters. Filters.	, ,	DOITE	ONAL			O V			
Check Card Order Other None 3. ADDITIONAL FEES									
X Deposit Account	1 250	. Env.	Commit	Emity					
Deposit Ассоция 08-3425	Pea	Enuty Fee	Fee	Fee	- Fee Description				
Numbor	Code	(\$)	Code	(\$)	res description	Fee Paid			
Account Human Genome Sciences, Inc.	1051	130	2051	65	Surcharge - late tiling tee or path				
Name The Director is authorized to (oneck authal apply)	1052	50	2052	25	Surcharge - late provisional filing t	ee or cover			
X Charge ree(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-Forust specification				
Charge up and complete and design and the participation of the	1812	2,530	1812		Non-English specification				
x application					For filing a request for on parte rocker Requesting publication of SIR prior				
Charge tee(s) indicated below, except for the filing fee	1804	920*	1804	920*	Examinet action				
to the above-identified deposit account.	1805	1,840*	1805	1,840"	Requesting publication of SIR after Examiner action				
FEE CALCULATION	1,257	110	225]	55	Extension for reply within first mont				
1. BASIC FILING FEE	1252	420	2252	210	Extension for reply within second n				
Large Entity Small Emity Fee Fee Fee Fee Fee <u>Fee Description</u> Fee Paid	1253	950	2253	475	Extension for reply within third mor				
Code (\$) Code (\$)	1254	1.480	2254	740	Extension for reply within fourth mu				
1001 770 2001 385 Utility tiling tee	1255 1401	2,010 330	2255 2401		• • • • • • • • • • • • • • • • • • • •	th			
1002 340 2002 170 Design thing tee 1003 530 2003 265 Prant hing tee	1402	330	2402	165 165	Notice of Appeal Filting a brief in support of an appeal				
1004 770 2004 385 Reissue filing tee	1403	290	2403	145	Request for oral hearing				
1005 160 2005 80 Provisional tiling tee	1451	1,510	i ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '			ceeding			
SUBTOTAL (1) (\$) 0.00	1452	110	2452	55	etibon to fevive – unavoidable				
	1453	1,330	2453	665	grigon to texing - ritity[eutroligi				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,330	2501	665	Utility issue tee (or reissue)	-			
Claims below Fee Paid	1502	480	2502	240	Pesign issue tou				
Total Claims -20" = x = independent	7503 1460	640 130	2503 1460	320 130	Plant issue too Petitions to the Corninssioner	 			
Claims Land " Land La	1807	50	1807						
Multiple Dependent =						·			
Large Entity Smail Entity Foo Foo Foo Foo	7806	180	7806	180	Submission of information Disclosure Recording each patent assignment				
Code (5) Code (\$)	8021	40	8021	40	property (times number at propertie	ise (se			
1202 18 2202 9 Claima in excess of 20 1201 86 2201 43 (ndependent claims in excess of 3	1809	7 7 0	2809	385	Filing a submission after timel reject (37 CFR 1 129(a))	IION			
1203 290 2203 145 Multiple dependent claims in excess of 5	отат	770	2810	385	For each additional invention to be examined (37CFR 1 129(b))				
1204 86 2204 43 ** Reissue ingependent claims	1801	770	2801	365	Request to Continued Examination	n (RCE)			
over original patent 1205 18 2205 9 ** Reissue claims in excess of 20	1802	802 900 1802 400 Request for expedited examination							
1205 18 2205 9 ** Reiseue claims in excess of 20 and over original patent	Other tee (specify)				of a design application				
SUBTOTAL (2) (\$) 000	'Requ	cad by E	388/C Fil	ing Fee	Paid SUBTOTAL (3)	(S) 0.00			
SUBTOTAL. (2) (5) 000 "Reduced by Basic Filing Fe6" or number previously paid, if gragier, For Reissues, see apove									
SUBMITTED BY				(Сотрыт (4 арріса)	o(a))				
Name (Pmil/Type) Lin J. Hyme) Registration No (Attorney/Agent) 45,414					Таврлопа (301) 2	51-6015			
					Date Octobe	r 2, 2003			
Signature 1 - 1, Hay									

88/12/83 18:84:18


<-0792U

3013098439 RightFAX

Page 881

TO: Auto-reply fax to 3013098439 COMPANY:

Auto-Reply Facsimile Transmission



TO:

Fax Sender at 3013098439

Fax Information Date Received: Total Pages:

8/12/03 5:59:56 PM [Eastern Daylight Time] 10 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received Cover Page ~=====>

Virth. Is.as at athe	Frue-HLL PATENT DEPT 3012484444 T-694 P 41 F 277
FAL TR	noiézimana
DATE. CLIEN MESS. COMP FAX FHON	T PF1+194 NGE S-aminer Devic Respect ANY. U.S. Peters of Trademary Office, Group 1000 (703) \$72-9:00
FROM PHON	,
Pace: Mees	Grenaging Curus 10 HARD COPY TO YES N
	For Transmission Amondment with Response suggested C.F.R. 312 (a to Paper No. 28 Comments of Transmission Under 77 C.F.R. 318 If your receipt of the transmission is in error, pieces notify this firm affine disability by collect call to employ at (41) one-5790 and sond the engined designation to us by entertimed a the address below.
	This transmission is antended for the sole use of the milliodist and entry to nature it is above, and may contain inflittening that is privileged, conflictful and execute from disclosure under applicable law. You are hereby outfiles that any quasamparfice, disciplination of the form of the framework of the disciplination appears of the disciplination appears of the disciplination of the first to arrive the first than the contained of t
	HUMAN CENOMI: SCIENCES, INC 9418 AFF West Archite, Maryinga Tubbu Telephone* (501) 510-5790 Faculatio, (301) 309-8439

3013098439

FAX TRANSMISSION

DATE:	August 12, 2003								
CLIENT	PF141 P 4								
MESSAGE	Examiner David Romeo								
COMPANY	U.S. Patent & Trademark Office, Group 1600								
FAX	(703) 872-9307								
PHONE:	(703) 305-4050								
FROM:	Lorna Charles								
PHONE:	(301) 251-6012								
PAGES (Inc	eluding Cover 10 HARD COPY TO YES x N								
MESSAG E:	Please enter the following documents in the file of Application No. 09/246,129:								
	Fee Transmittal								
	mendment With Response Under 37 C.F.R. §1.116 to Paper No. 28								
	Certificate of Transmission Under 37 C.F.R. §1.8								

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (301) 610-5790 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

HUMAN GENOME SCIENCES, INC. 9410 Key West Avenue, Rockville, Maryland 20850 Telephone: (301) 610-5790 Facsimile: (301) 309-8439

PTC/SB/17 (05-03)
Approved for use through 04/30/2003 QMB 0551-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Linder the Paperwork Reduction Act of 1995, no persons are requ	aguired to respond to a collection of information unless it displays a valid OMB control number							
		Complete If Known						
FEE TRANSMITTAL	Application Number			er	09/246,129-Conf. #5810			
for FY 2003		Filing Date				February 8, 1999		
Ethective 01/01/2003, Patent toos are subject to annual revision		First Named Inventor			Guo-Liang Yu			
	Examiner Name			D. Romeo				
Applicant claims small entity status See 37 CFR 1 27		Art Unit 164			1647			
TOTAL AMOUNT OF PAYMENT (\$) 0 00	Αποπιθy Docket No.			o. [PF141P4	¥		
METHOD OF PAYMENT (check all that apply)	T	FEE CALCULATION (continued)						
Check Credit Money Other None X Deposit Account	3. 4	יודוסםי	DNAL	FEES				· • • • •
Deposii	Larg	e Entity		Enuty	_			
Account Number 08-3425		F ee (\$)	Foo	Foe (\$)		Fee Des	cription	Fee Paid
Depo ₂ , r	Code				C. managemen	HER SHARE	2A ar auth	75272
Account Human Genome Sciences, Inc.	7057	- 430	2051	65		- late filing for	ona: filing fee or cover	}
The Director is heroby authorized to. (cneck all that apply)	1052	50	2052	25	shoet.	IMA- MOAIG	arrest falls of total of polytical	
Charge tes(s) indicated pelow X Credit any overpayments	1053	730	1053	130	Non-Engle	sh specificatio	on	
X Charge any addutorial fee(s) during the pendency of this application	1812	2,520	7872	2,520	For filing a	request for ex	рале гезлатильного	
Charge tee(a) indicated below. except for the filing the	1804	920*	1804	920"	Requesting Examiner a		ot SIR prioi 10	
to the above-dentified deposit account	1805	1.840*	1805	1,840*	Requesting	g publication (or SiR after	
FEE CALCULATION	1251	110	2251	55	Evaminet :	action for reply with	n first month	-
1. BASIC FILING FEE	1252	410	2252	205		• •	n second month	
Large Entity Small Entity	1253	930	2253	465	Ехтелькой	10 r⊏ply with	n third month	
Fee Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	1254	1,450	2254	725	Extension	tor reply with	A fourth month	
1001 750 2001 \$75 Utiny filing tee	1255	1,970	2255	985	Extension	tor reply with	तक्षावस्य वर्गाते व	
1002 330 2002 165 Design filing fee	1401	320	2401	160	Notice of A	of Appeal		
1003 520 2003 260 Plant filing tes	7402	320	2402	160		рпет іп зарроп of an appeai		ļ
1004 750 2004 375 Reissue filing fee	1403	280	2403 1451	140	-	roral nearing		
	1457	1,510 110	2452	1,510		Levive – huzh Levive – huzh	Nië use proceeding pidable	
SUBTOTAL (1) (\$) 0 00	1453	1,300	2453	650	_	ievive - unititi		i
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501	650	Utility issue	a fee (or reiss	u¢)	
Ears Fee from Claims pelow Fee Paid	1502	470	2502	235	Деъідп ізаі	ue fee		
Total Claints -20" = x =	7,508	630	2503	315	Plant (8848	166		
andependent 3" = x	1460	130	1460	130	Petitions to	the Commis	sione <i>r</i>	
Multiple Dependent =	1807	07 50 1807 50 Processing fee unger 37 CFR 1 17(q)		CFR 1 17(q)				
Large Entity Small Entity	1806	180	1806	180	Submissiol	n of Intormatic	on Disclosure Simi	
Feb Fec Fee Fee Fee Description	8023	4D	8021	40			issignment per of properties)	
1202 18 2202 9 Claims in excess of 20	1809	9 750 2809 375 Filing a submission after final rejection						
1201 84 2201 42 Independent claims in excess of 3	1810	7 5 0	2810	375	For each a	37 CFR 1.129(a)) For each aggittorial invention to be		
1203 280 2203 140 Multiple dependent dalm, if not paid 1204 84 2204 82 "* Rejasus independent claims		- 1			examined (37CFR 1.129(b))			
over original patent	1801 750 2801 375 Request for Continued Examination (RCE)		 					
1205 18 2205 9 "Reissue claims in excess of 20 and over original patent	Other tee (specify)			application				
SUBTOTAL (2) (\$) 0.00 "or number previously paid, if greater, For Reissues, see apove	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0.00						0.00	
SUBMITTED BY	5		~			Complete	(f аррісали)	
Name (Prod/Type) Lin J., Hymel	Registi (Amorna	ration No sylagent)	45	,434		Telephone	(301) 251-6015	
Signature 1 - U						Days	August 12, 200	3
1								

VIA FAX AUGUST 12, 2003

Docket No.: PF141P4

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Yu et al

Application No.: 09/246,129

Group Art Unit: 1647

Filed: February 8, 1999

Examiner: D. Romeo

For:

Tumor Necrosis Factor-Gamma

AMENDMENT WITH RESPONSE UNDER 37 C.F.R. § 1.116 TO PAPER NO. 28

Mailstop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Advisory Action mailed July 22, 2003, and the telephone interview held with the Examiner August 11, 2003, please consider the following amendments and remarks. Submitted concurrently herewith is a Certificate of fax transmission.

Prior to further examination, Applicants respectfully request entry of the following amendments.

- Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.
- Remarks begin on page 6 of this paper.

Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-41. (Cancelled)

- 42. (Currently Amended) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) amino acid residue -27 to amino acid residue +147 as set forth in SEQ ID
 NO:2;
 - (b) amino acid residue -26 to amino acid residue +147 as set forth in SEQ ID NO:2;
 - (c) amino acid residue +1 to amino acid residue +147 as set forth in SEQ ID NO:2;
 - (d) a full-length polypeptide having the amino acid sequence expressed by the cDNA plasmid contained in ATCC Deposit No. 75927;
 - (e) a full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence expressed by the cDNA plasmid contained in ATCC Deposit No. 75927; and
 - (f) a polypeptide having the amino acid sequence, excluding the signal sequence, expressed by a recombinant cell comprising encoded by the cDNA plasmid contained in ATCC Deposit No. 75927, wherein said amino acid sequence is encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.
- 43. (Previously presented) The isolated polypeptide of claim 42 consisting of amino acid residue -27 to amino acid residue +147 as set forth in SEQ ID NO:2.
- 44. (Previously presented) The isolated polypeptide of claim 42 consisting of amino acid residue -26 to amino acid residue +147 as set forth in SEQ ID NO:2.

Appl'n Serial No.: 09/246,129

- 45. (Previously presented) The isolated polypeptide of claim 42 consisting of amino acid residue +1 to amino acid residue +147 as set forth in SEQ ID NO:2.
- 46. (Previously presented) The isolated polypeptide of claim 42 consisting of a full-length polypeptide having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 75927.
- 47. (Previously presented) The isolated polypeptide of claim 42 consisting of a full-length polypeptide, excluding the N-terminal methionine residue, having the amino acid sequence expressed by the human cDNA contained in ATCC Deposit No. 75927.
- 48. (Previously presented) The isolated polypeptide of claim 42 consisting of a polypeptide having the amino acid sequence expressed by a recombinant cell comprising the human cDNA contained in ATCC Deposit No. 75927.

49-51. (Cancelled)

- 52. (Previously presented) The isolated polypeptide of claim 42 wherein said polypeptide is fused to a heterologous polypeptide.
- 53. (Previously presented) The isolated polypeptide of claim 52 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
- 54. (Previously presented) A composition comprising the polypeptide of claim 42 and a pharmaceutically acceptable carrier.
- 55. (Previously presented) An isolated polypeptide encoded by a nucleic acid molecule consisting of a polynucleotide sequence selected from the group consisting of:
 - (a) a polynucleotide sequence consisting of at least 30 contiguous nucleotides of nucleotides 783 to 1304 of SEQ ID NO:1; and
 - (b) a polynucleotide sequence consisting of at least 30 contiguous nucleotides of the open reading frame encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.

Appl'n Serial No.: 09/246,129 3 PF141P4

56. (Previously presented) The isolated polypeptide of claim 55 encoded by a polynucleotide which consists of (a).

57-58. (Cancelled)

59. (Previously presented) The isolated polypeptide of claim 55 encoded by a polynucleotide which consists of (b).

60-61. (Cancelled)

- 62. (Previously presented) The isolated polypeptide of claim 55 wherein said polypeptide is fused to a heterologous polypeptide.
- 63. (Previously presented) The isolated polypeptide of claim 62 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
- 64. (Previously presented) A composition comprising the polypeptide of claim 55 and a pharmaceutically acceptable carrier.
- 65. (Previously presented) An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence consisting of at least 30 contiguous amino acid residues of SEQ ID NO:2; and
 - (b) an amino acid sequence consisting of at least 30 contiguous amino acid residues encoded by the cDNA plasmid contained in ATCC Deposit No. 75927.
- 66. (Previously presented) The isolated polypeptide of claim 65 which consists of (a).

67-68. (Cancelled)

69. (Previously presented) The isolated polypeptide of claim 65 which consists of (b).

70-71. (Cancelled)

Appl'n Serial No.: 09/246,129

4

PF141P4

- 72. (Previously presented) The isolated polypeptide of claim 65 wherein said polypeptide is fused to a heterologous polypeptide.
- 73. (Previously presented) The isolated polypeptide of claim 72 wherein said heterologous polypeptide is the Fc domain of immunoglobulin.
- 74. (Previously presented) A composition comprising the polypeptide of claim 65 and a pharmaceutically acceptable carrier.

75-94. (Cancelled)